ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
46 hedge funds and large institutions have $219M invested in Adaptimmune Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
46
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$3.46M | |
| 2 | +$2.79M | |
| 3 | +$1.9M | |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.41M |
| 5 |
Renaissance Technologies
New York
|
+$983K |
Top Sellers
| 1 | -$8.6M | |
| 2 | -$3.28M | |
| 3 | -$2.77M | |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$1.16M |
| 5 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$849K |